Introduction

The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most commonly mutated signalling pathways in human cancers. While a range of small molecule inhibitors have been developed to inhibit the upstream and downstream effectors of this pathway, resistance remains a significant challenge.

After a successful first meeting in 2023, this next edition of the joint EACR and Boehringer Ingelheim virtual conference will focus on both the basic and clinical aspects of regulating signalling through the MAPK pathway and its role in cancer. A thorough understanding of the mechanisms of intrinsic and adaptive resistance is crucial for the development of more effective agents. The programme will include new insights on the mechanism of action of and resistance mechanisms to the new generation of pan-RAS inhibitors.

Register now

Target audience

Those in academia and industry that are interested in the role of the MAPK pathway in the context of genetically targeted and immune-based anticancer therapies. The meeting will focus on both the mechanistic aspects of gene regulation, target validation, and drug development, as well as emerging clinical and translational opportunities.

Topics to be covered:

• Regulation of MAPK signalling
• Drug resistance mechanisms
• Rational combination therapies
• Cross-resistance to immune modulators

Scientific Programme Committee:

• René Bernards (Chair), The Netherlands Cancer Institute, Netherlands
• Marco Hofmann, Boehringer Ingelheim, Austria
• Chiara Ambrogio, University of Torino, Italy
• Anna Obenauf, Research Institute of Molecular Pathology, Austria

We are grateful to Boehringer Ingelheim for their partnership on this conference. Through representation on the Scientific Programme Committee, they have helped to build the exceptional scientific programme and their financial contribution enables us to keep the registration fees as low as possible, from only €30 for EACR members. They are one of our valued EACR Industry Partners. 

Follow us on X for updates @EACRnews

Image courtesy of Anna Obenauf at the Obenauf Lab, IMP Vienna